ArticleFrontiers in oncology2025
Photobiomodulation therapy approach to a rare phenomenon of radiation recall reaction triggered by cisplatin in a cervical cancer patient: a case report and scoping review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Radiation recall reaction (RRR) is a rare and poorly understood phenomenon of tissue radiotoxicity. It is typically triggered by exposure to certain agents, most commonly cytotoxic drugs such as cisplatin. We conducted a scoping review following the methodology proposed by the JBI collaboration and PRISMA-ScR extension. It aimed to map the evidence concerning the treatment of RRR triggered by cisplatin. Methods: Searches were performed in PubMed/MEDLINE, EMBASE, Web of Science Core Collection, Cochrane Database, and ProQuest™ on March 9, 2025. Eligible studies included primary research, guidelines, and study protocols that addressed RRR as a primary or secondary outcome. A case report was also described. Results: Eight studies were included, and the main treatments for RRR were topical steroids and antihistamines. A 36-year-old woman with cervical cancer developed intense hyperpigmentation in the inguinal, vulvar, and anal areas, along with anal and labial fissures, dry desquamation in the inguinal region, and vaginal stenosis, 3 days after cisplatin. The diagnosis was RRR affecting mucosa and skin in the intimate region. Photobiomodulation therapy (PBMT) was initiated using lasers emitting wavelengths of 660 and 808 nm for tissue repair in the vulva, anus, and groin, and LEDs emitting 450 nm for vaginal stenosis and 590 nm for hyperpigmentation. Following the first PBMT session, the patient showed an excellent clinical response after 1 week, with a significant reduction in the severity of RRR. Conclusion: PBMT appears to be a viable, non-invasive, and low-cost treatment option for RRR, with no reported side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.